Eric D. Hsi

29.6k total citations · 1 hit paper
405 papers, 12.2k citations indexed

About

Eric D. Hsi is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Eric D. Hsi has authored 405 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 245 papers in Pathology and Forensic Medicine, 149 papers in Genetics and 146 papers in Oncology. Recurrent topics in Eric D. Hsi's work include Lymphoma Diagnosis and Treatment (240 papers), Chronic Lymphocytic Leukemia Research (102 papers) and Viral-associated cancers and disorders (75 papers). Eric D. Hsi is often cited by papers focused on Lymphoma Diagnosis and Treatment (240 papers), Chronic Lymphocytic Leukemia Research (102 papers) and Viral-associated cancers and disorders (75 papers). Eric D. Hsi collaborates with scholars based in United States, Canada and Germany. Eric D. Hsi's co-authors include Juraj Bodo, Jaroslaw P. Maciejewski, Brad Pohlman, Raymond R. Tubbs, Alexandru Almasan, Bruce D. Cheson, Brian T. Hill, Sin‐Ho Jung, Jeffrey L. Johnson and Serhan Alkan and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Eric D. Hsi

390 papers receiving 12.0k citations

Hit Papers

Pralatrexate in Patients ... 2011 2026 2016 2021 2011 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
    2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Eric D. Hsi 6.0k 4.7k 3.5k 3.2k 2.6k 405 12.2k
Paul J. Kurtin 5.1k 0.9× 3.6k 0.8× 2.8k 0.8× 3.3k 1.0× 2.2k 0.8× 235 11.4k
Armando López‐Guillermo 8.4k 1.4× 5.2k 1.1× 4.4k 1.3× 1.8k 0.6× 2.4k 0.9× 244 11.5k
Miguel Á. Piris 8.5k 1.4× 6.3k 1.3× 3.9k 1.1× 3.6k 1.1× 2.8k 1.1× 328 14.2k
Izidore S. Lossos 5.8k 1.0× 4.3k 0.9× 2.5k 0.7× 2.9k 0.9× 2.8k 1.0× 353 10.8k
German Ott 8.7k 1.5× 6.2k 1.3× 4.0k 1.1× 2.7k 0.9× 2.0k 0.7× 336 12.9k
Luis Fayad 6.3k 1.1× 5.5k 1.2× 2.7k 0.8× 1.3k 0.4× 1.7k 0.6× 334 9.7k
Franck Morschhauser 8.8k 1.5× 6.7k 1.4× 3.7k 1.1× 1.9k 0.6× 2.3k 0.9× 447 12.3k
Myron S. Czuczman 6.5k 1.1× 4.6k 1.0× 3.5k 1.0× 2.0k 0.6× 1.9k 0.7× 241 10.4k
Alessandro M. Gianni 3.1k 0.5× 3.7k 0.8× 3.4k 1.0× 2.1k 0.6× 2.1k 0.8× 205 9.4k
Francesc Bosch 5.6k 0.9× 3.4k 0.7× 4.3k 1.2× 2.0k 0.6× 2.1k 0.8× 243 8.7k

Countries citing papers authored by Eric D. Hsi

Since Specialization
Citations

This map shows the geographic impact of Eric D. Hsi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric D. Hsi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric D. Hsi more than expected).

Fields of papers citing papers by Eric D. Hsi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric D. Hsi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric D. Hsi. The network helps show where Eric D. Hsi may publish in the future.

Co-authorship network of co-authors of Eric D. Hsi

This figure shows the co-authorship network connecting the top 25 collaborators of Eric D. Hsi. A scholar is included among the top collaborators of Eric D. Hsi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric D. Hsi. Eric D. Hsi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Weina, Adam Bagg, Prasad Koduru, et al.. (2023). Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. Leukemia Research. 130. 107309–107309. 4 indexed citations
3.
Hartmann, Sylvia, Stefan Dojcinov, Snježana Dotlić, et al.. (2023). The spectrum of nodular lymphocyte predominant Hodgkin lymphoma: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 483(4). 451–463. 4 indexed citations
4.
Dotlić, Snježana, Sarah E. Gibson, Sylvia Hartmann, et al.. (2023). Lymphomas with plasmablastic features: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 483(5). 591–609. 1 indexed citations
5.
Gruver, Aaron M., Bradley L. Ackermann, Ryan D. Morrison, et al.. (2021). Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. Journal of Clinical Pathology. 75(9). 636–642. 5 indexed citations
6.
Gurnari, Carmelo, Simona Pagliuca, Lisa Durkin, et al.. (2021). Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood. 137(26). 3685–3689. 54 indexed citations
7.
Vega, Francisco, Catalina Amador, Amy Chadburn, et al.. (2021). Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Modern Pathology. 35(3). 306–318. 20 indexed citations
8.
Rogers, Heesun J., Xiaoqiong Wang, Yan Xie, et al.. (2020). Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology. 95(7). 799–808. 22 indexed citations
9.
Zhao, Xiaoxian, et al.. (2020). Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. Human Pathology. 107. 1–8. 4 indexed citations
10.
Foucar, Kathryn, Eric D. Hsi, Sa A. Wang, et al.. (2020). Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology. 42(4). 418–422. 15 indexed citations
11.
12.
Purcell, James W., Jonathan A. Hickson, Melvin Fox, et al.. (2018). LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates. Cancer Research. 78(14). 4059–4072. 136 indexed citations
13.
Yu, Xinfang, Wei Li, Qipan Deng, et al.. (2018). MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Research. 78(10). 2457–2462. 81 indexed citations
14.
Rubenstein, James L., Eric D. Hsi, Jeffrey L. Johnson, et al.. (2013). Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202). Journal of Clinical Oncology. 31(25). 3061–3068. 320 indexed citations
15.
Frei, Emil, Carlo Visco, Zijun Y. Xu‐Monette, et al.. (2013). Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. Journal of Clinical Pathology. 66(11). 956–961. 19 indexed citations
16.
O’Connor, Owen A., Barbara Pro, Lauren Pinter‐Brown, et al.. (2011). Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 29(9). 1182–1189. 439 indexed citations breakdown →
17.
Farha, Samar, Kewal Asosingh, Weiling Xu, et al.. (2011). Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood. 117(13). 3485–3493. 107 indexed citations
18.
Culp, Patricia, Donghee Choi, Yongke Zhang, et al.. (2010). Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms. Clinical Cancer Research. 16(2). 497–508. 62 indexed citations
19.
20.
Makishima, Hideki, Heather Cazzolli, Hadrian Szpurka, et al.. (2009). Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies. Journal of Clinical Oncology. 27(36). 6109–6116. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul J. Kurtin Breakdown of academic impact, for papers by Armando López‐Guillermo Breakdown of academic impact, for papers by Miguel Á. Piris Breakdown of academic impact, for papers by Izidore S. Lossos Breakdown of academic impact, for papers by German Ott Breakdown of academic impact, for papers by Luis Fayad Breakdown of academic impact, for papers by Franck Morschhauser Breakdown of academic impact, for papers by Myron S. Czuczman Breakdown of academic impact, for papers by Alessandro M. Gianni Breakdown of academic impact, for papers by Francesc Bosch
Rankless by CCL
2026